secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001104659-23-055815
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar reports Q1 net loss of $8.6M; cash at $12.7M with runway into Q4 2023
-------------------------------------------------------------------------------

- Net loss of ($8.6M) or ($0.76)/share vs ($6.1M) or ($1.00)/share in Q1 2022.
- Cash and equivalents $12.7M at March 31, 2023, down from $19.9M at Dec 31, 2022.
- R&D expense rose to $6.7M from $3.9M YoY on clinical, manufacturing costs.
- G&A expense decreased to $2.1M from $2.3M YoY driven by lower professional fees.
- Enrolling pivotal iopofosine trial in Waldenstrom's; topline data expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923055815/0001104659-23-055815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923055815/tm2314664d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-055815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer